Patents by Inventor Armin Sepp
Armin Sepp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170210814Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: March 27, 2017Publication date: July 27, 2017Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 9629909Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: June 18, 2013Date of Patent: April 25, 2017Assignee: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20150210767Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: ApplicationFiled: April 9, 2015Publication date: July 30, 2015Inventors: Inusha DE SILVA, Armin SEPP, Adriaan Allart STOOP
-
Patent number: 9028817Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: GrantFiled: October 25, 2010Date of Patent: May 12, 2015Assignee: Glaxo Group LimitedInventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20140187762Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having the desired activity using a change in the optical properties of the genetic elements. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.Type: ApplicationFiled: November 21, 2013Publication date: July 3, 2014Applicant: MEDICAL RESEARCH COUNCILInventors: Andrew Griffiths, Dan Tawfik, Armin Sepp
-
Publication number: 20140112929Abstract: The invention relates to TNFR1 binding proteins, in particular those which are capable of preventing dimerisation of TNFR1 chains, and to their use in therapy.Type: ApplicationFiled: June 15, 2012Publication date: April 24, 2014Applicant: Glaxo Group LimitedInventors: Thil Dinuk Batuwangala, Andrew Sanderson, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20130309227Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: June 18, 2013Publication date: November 21, 2013Applicant: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Greogory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8497244Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: January 23, 2012Date of Patent: July 30, 2013Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20130078216Abstract: The present invention relates to molecules that can be targeted to the liver. These liver targeting molecules (e.g.fusions and conjugates) comprise proteins, antibodies or antibody fragments such as immunoglobulin (antibody) single variable domains (dAbs) and also one or more additional molecules which it is desired to deliver to the liver such as interferons. The invention further relates to uses, formulations, compositions and devices comprising such liver targeting molecules. The invention also relates to immunoglobulin (antibody) single variable domains which bind to hepatocytes.Type: ApplicationFiled: January 13, 2011Publication date: March 28, 2013Inventors: Grainne Dunlevy, Steven Holmes, Zhi Hong, Armin Sepp, Adam Walker
-
Publication number: 20120213787Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: ApplicationFiled: October 25, 2010Publication date: August 23, 2012Inventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20120114651Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8129503Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: October 23, 2006Date of Patent: March 6, 2012Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8084213Abstract: The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.Type: GrantFiled: January 17, 2007Date of Patent: December 27, 2011Assignee: Domantis LimitedInventors: Armin Sepp, Andrew Griffiths
-
Publication number: 20110301335Abstract: The invention relates to anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: ApplicationFiled: February 17, 2010Publication date: December 8, 2011Inventors: Stephen Duffield, Carolyn Enever, Haiqun Liu, Oliver Schon, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20110159003Abstract: Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.Type: ApplicationFiled: January 24, 2007Publication date: June 30, 2011Applicant: Domantis LimitedInventors: Ian Tomlinson, Allart Adriaan Stoop, Armin Sepp, Inusha De Silva, Caroline J. Dimech, Malgorzata Pupecka, Rudolf M.T. De Wildt, Philip D. Drew, Steve Holmes
-
Publication number: 20110086019Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 3, 2008Publication date: April 14, 2011Applicant: Domantis LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Armin Sepp
-
Patent number: 7897341Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having the desired activity using a change in the optical properties of the genetic elements. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.Type: GrantFiled: June 18, 2007Date of Patent: March 1, 2011Assignee: Medical Research CouncilInventors: Andrew Griffiths, Dan Tawfik, Armin Sepp
-
Publication number: 20100056439Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.Type: ApplicationFiled: December 5, 2006Publication date: March 4, 2010Applicant: DOMANTIS LIMITEDInventors: Roland Beckmann, Rudolf M T De Wildt, Steve Holmes, Olga Ignatovich, Laurent S Jespers, Haiqun Liu, Malgorzata Pupecka, Armin Sepp, Michael Steward
-
Publication number: 20100034831Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: October 23, 2006Publication date: February 11, 2010Inventors: Rudolf M.T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20090325236Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having the desired activity using a change in the optical properties of the genetic elements. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.Type: ApplicationFiled: December 19, 2008Publication date: December 31, 2009Inventors: Andrew Griffiths, Dan Tawfik, Armin Sepp